Biotech Bausch Health’s Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 November 6, 2026
Biotech Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026 November 6, 2026
Biotech U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme’s ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer November 6, 2026
Biotech Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 November 6, 2026
Biotech Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update November 6, 2026
Biotech HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE November 6, 2026